Micromet, Inc (MITI) Closes On $40M from Biotechnology Investors
Micromet, Inc. (MITI) announced they successfully raised $40M this week in private placement financing for research and development. The company, which develops antibodies for cancer treatments, publicized the transaction Sept. 30 and closed Oct. 2. Those who invested include Index Ventures Growth, Abingworth, DAFNA Capital Management, LLC, and Merlin Nexus. Micromet board members and affiliates also participated. "We are very pleased to have completed this financing under these challenging market conditions,” said Micromet's President and CEO Christian Itin, “and we were gratified by the strong support of Micromet and the significant interest of the investors in this private placement. The…